SPLASH: Study Evaluating Metastatic Castrate Resistant Prostate Cancer Treatment Using 177Lu-PNT2002 PSMA Therapy After Second-line Hormonal Treatment

Grants and Contracts Details

StatusActive
Effective start/end date8/5/21 → 6/15/26

Funding

  • POINT Biopharma Incorporated: $220,272.00